Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 14Gynecologic 7Dermatologic 7Head & Neck 6Genitourinary 6Thoracic 5Gastrointestinal 4Sarcoma 2Other solid neoplasm 2Lymphoid 1Endocrine 1CNS 1

Conditions

Sarcoma 22Melanoma 6Histiocytoma, Malignant Fibrous 6Gastrointestinal Stromal Tumors 5Osteosarcoma 4Neoplasm Metastasis 4Gliosarcoma 4Neuroblastoma 3Hemangiosarcoma 3Chordoma 3Bone Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma 2Lung Neoplasms 2Liver Neoplasms 2Liposarcoma 2Head and Neck Neoplasms 2Glioblastoma 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Bile Duct Neoplasms 2

Interventions

pembrolizumab 7Cyclophosphamide 6Nivolumab 4fludarabine 3spartalizumab 2aldesleukin 2Trastuzumab 2Standard of Care 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Irinotecan 2Ipilimumab 2Gemcitabine 2zanidatamab 1vocimagene amiretrorepvec 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tinostamustine 1talazoparib 1sarilumab 1sargramostim 1regorafenib 1pexidartinib 1pertuzumab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Ipilimumab × Sarcoma × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡